Dr Naveen Vasudev talks to ecancer about the PRISM study, a randomised phase II study looking at nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma.
He begins by talking about the background to the study, touching on results that have been seen from prior studies in kidney cancer and melanoma that clearly there is a relationship between the dose of IPI and its associated toxicity, but the frequency in which IPI is given has also been explored.
Dr Vasudev then talks about the eligibility for study. Patients were required to have treatment naive locally advanced or metastatic RCC with at least a component of clear cell histology. He then goes into further detail about the methodology used.
He concludes by saying the study met it's primary endpoint. The proportion of patients experiencing a grade 3 or 4 treatment related adverse event was significantly lower amongst patients receiving IPI every 12 weeks vs 3 weekly dosing.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.